Seven years ago, Suzanne Hebert was diagnosed with metastatic breast cancer that spread to her liver and bones. After four rounds of chemotherapy and decreasing response rates, she decided it was time for a change. That change came after advice from a friend, who also had advanced breast cancer, and was enrolled on a clinical trial at MD Anderson.
The trial combined two drugs, everolimus, and a hormone therapy called arimidex. A different trial named BOLERO-2, or Breast Cancer Trials of Oral Everolimus, showed that combining everolimus with a different hormone therapy, exemestane, dramatically improved progression-free survival for women with advanced breast cancer.
This week, the BOLERO-2 study was presented at the San Antonio Breast Cancer Symposium by Gabriel Hortobagyi, M.D., professor and chair of the Department of Breast Medical Oncology at MD Anderson.
To learn more about the BOLERO-2 trial, visit http://bit.ly/rt8ObP.
« Hide
